Drug intelligence / Profile preview

ALF601

Development stage: Preclinical
Lead developer: Beijing Allife Medicine Technology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ALF601 is an investigational iPSC-derived red blood cell therapy developed by Allife Medical Science and Technology for the treatment of severe anemia. The product is manufactured by differentiating induced pluripotent stem cells (iPSCs) into mature, functional red blood cells (erythrocytes). These manufactured cells are intended to be administered to patients to restore oxygen-carrying capacity and alleviate symptoms of severe anemia, potentially providing an alternative to traditional donor-based blood transfusions. ALF601 is currently in the preclinical stage of development.

Beyond the preview

Go deeper on ALF601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALF601.

Explore the full profile